Screener
Celldex Therapeutics CLDX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
FAQ
- What is Celldex Therapeutics's cash & equivalents?
- Celldex Therapeutics (CLDX) reported cash & equivalents of $47.45M in Q2 2026.
- How has Celldex Therapeutics's cash & equivalents changed year-over-year?
- Celldex Therapeutics's cash & equivalents increased by 105.9% year-over-year, from $23.04M to $47.45M.
- What is the long-term trend for Celldex Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Celldex Therapeutics's cash & equivalents has grown at a -8.0% compound annual growth rate (CAGR), from $43.84M to $28.87M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Celldex Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude